An independent judging panel will select three finalists from the submissions.
The Society for Clinical Research Sites (SCRS), a global trade organization for clinical research sites, announced that it is accepting submissions for its annual Site Patient Recruitment Innovation Award (SPRIA), which recognizes sites that employ innovative strategies to achieve enrollment success. An independent judging panel will select three finalists from the submissions. The finalists will be invited to attend the Site Solutions Summit with a complimentary registration. At the summit, the finalists will present their plans to an audience of executives from sites, sponsors, and CROs. The judging panel then will determine the winner. Nominations forms can be downloaded on the Global Site Solutions Summit website. Completed form should be sent to SPRIA@myscrs.org by July 31, 2015.
The Global Site Solutions Summit takes place October 8-11, at Amelia Island, FL.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.